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Plasma human immunodeficiency virus type 1 (HIV-1) turnover and kinetics were studied in children aged
15 days to 2 years following the initiation of a triple antiretroviral drug regimen consisting of zidovudine, lami-
vudine, and nevirapine. HIV-1 turnover was at least as rapid as that previously described in adults; turnover
rates were more rapid in infants and children aged 3 months to 2 years than in infants less than 3 months of
age. These data confirm the central role of HIV-1 replication in the pathogenesis of vertical HIV-1 infection and
reinforce the importance of early, potent combination therapies for the long-term control of HIV-1 replication.
Improvements in assays to detect and quantify human im-
munodeficiency virus type 1 (HIV-1) RNA in peripheral blood
and tissues have allowed the appreciation of the central role of
HIV-1 replication in HIV-1 pathogenesis (5–7). By using mo-
lecular techniques, HIV-1 can be detected in peripheral blood
plasma and mononuclear cells shortly after infection (16, 24,
25). Within weeks of infection, plasma HIV-1 RNA copy num-
bers ranging from 105 to 107 per ml of plasma have been doc-
umented.
During primary infection in adults, peak plasma HIV-1
RNA levels fall by 100- to 1,000-fold within 1 to 2 months after
the onset of symptoms (8, 24). This decline is observed even in
the absence of antiretroviral therapy; host immune responses
(1, 2, 8) or exhaustion of permissive host cells (20) is believed
to contribute to this phenomenon. By 4 to 6 months after
primary infection, a steady-state plasma HIV-1 RNA level is
reached (13, 24); this steady-state plasma HIV-1 RNA level
has been found to be predictive of the rate of subsequent
disease progression and survival independent of other param-
eters such as CD4 lymphocyte count. The analysis of changes
in plasma HIV-1 RNA levels following the initiation of potent
antiretroviral therapies to perturb the virus-host steady state
has allowed an improved understanding of the dynamics of
HIV-1 replication in vivo (3, 4, 6, 7, 18, 19, 27). From such
studies, it has been calculated that an average of 1010 HIV-1
virions are produced daily in adults with established disease.
These studies have formed the basis for a model of HIV-1
replication in which the majority of plasma virions (.93 to
99%) are produced by productively infected CD4 T lympho-
cytes, while smaller contributions (,10%) to the plasma virion
pool are made by populations of long-lived cells (e.g., macro-
phages) and latently infected lymphocytes (18).
Rapid increases in the plasma HIV-1 RNA copy numbers to
105 to 107 copies per ml of plasma have also been documented
in vertically infected infants during the first weeks of life (15,
17, 25). In contrast to the natural history of HIV-1 RNA levels
following primary infection in adults, plasma HIV-1 RNA lev-
els remain high (mean 105 copies per ml of plasma) over the
first 2 years of life. After the first 1 to 2 years of life, a reduction
in plasma HIV-1 RNA (mean, 20.2 to 20.3 log decline per
year) has been observed in vertically infected children that
continues through 5 to 6 years of age (12, 14, 16). As observed
in infected adults, higher plasma HIV-1 RNA levels are inde-
pendently associated with increased risk of progression to
AIDS or death in older children (14, 16, 26, 30). Additionally,
antiretroviral therapy-induced reductions in plasma HIV-1
RNA have been associated with clinical benefit in both chil-
dren (16) and adults (23).
Little information regarding the kinetics of HIV-1 replica-
tion in vertically infected infants and children is available. We
therefore undertook a study in which potent antiretroviral
therapies were used to probe the kinetics of HIV-1 replication
in infants and children. In this study, a triple antiretroviral drug
regimen consisting of zidovudine (ZDV), lamivudine (3TC),
and nevirapine (NVP) was administered to infants and chil-
dren aged 15 days to 2 years with limited or no prior antiret-
roviral therapy. Frequent blood sampling for plasma HIV-1
RNA copy number following the initiation of antiretroviral
therapy allowed the estimation of HIV-1 kinetic parameters.
The implications of these studies regarding the pathogenesis
and therapy of vertical HIV-1 infection are discussed.
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MATERIALS AND METHODS
Study design. This open-label, phase I/II study was conducted at 13 Pediatric
AIDS Clinical Trials Group sites, including Bellevue Hospital—New York Uni-
versity, Boston Children’s Hospital—Boston City Hospital, University of Mas-
sachusetts—Baystate Medical Center, Children’s Hospital—Philadelphia, Duke
University, State University of New York Health Science Center at Syracuse,
University of Mississippi, University of California—Los Angeles, University of
California—San Francisco, Medical University of South Carolina, and Tulane
University. The full details of this study will be described separately (unpublished
data).
This study was approved by the human subject committees at the participating
sites, and written informed consent was obtained from the children’s legal guard-
ians. The guidelines of the U.S. Department of Health and Human Services
governing experimentation in humans were followed.
Study medications. Infants 15 to 29 days old at the time of enrollment received
the following doses of study drugs: ZDV (Retrovir; Glaxo Wellcome), 4 mg/kg
three times daily through 29 days of age, then 160 mg per m2 of body surface area
three times a day beginning at 30 days of age; 3TC (Epivir; Glaxo Wellcome),
2 mg/kg every 12 h through 29 days of age, then 4 mg/kg every 12 h beginning at
30 days of age; NVP (Viramune; Boehringer-Ingelheim), 5 mg/kg once daily for
14 days, then 120 mg per m2 of body surface area for 14 days, and then 200 mg
per m2 every 12 h. Infants who were 30 days or older at the time of enrollment
received the following doses of study drugs: ZDV, 160 mg per m2 of body surface
area three times a day; 3TC, 4 mg/kg every 12 h; and NVP, 120 mg per m2 of body
surface area for 14 days and then 200 mg per m2 every 12 h. All medications were
administered as a syrup or a suspension, at concentrations of 10 mg/ml.
Quantification of plasma HIV-1 RNA copy number by reverse transcriptase
PCR. HIV-1 RNA was quantified in 200 ml of EDTA-anticoagulated plasma
(stored at 270°C within 6 hours after phlebotomy) by PCR after reverse tran-
scription (Amplicor; Roche). The lower detection limit of the assay is 400 copies
of HIV-1 RNA per ml of plasma. All assays were performed in a single labora-
tory that participates in an ongoing quality certification program for HIV-1 RNA
quantitation sponsored by the National Institutes of Health. Sequential samples
through 12 weeks of therapy from individual patients were assayed in batches to
avoid variability between assays.
RESULTS
Patient population. Sixteen infants aged 15 days to 2 years
enrolled in this study, and therapy was initiated with the triple
antiretroviral drug regimen of ZDV, 3TC, and NVP. Subjects
were stratified into two age cohorts (seven infants of #3
months of age and nine infants or children of .3 months). The
stratification was performed because it was hypothesized that
viral kinetics of infants who were experiencing primary infec-
tion (#3 months of age) and of those who were past the period
of primary infection (.3 months) might differ.
All 16 infants received a minimum of 12 weeks of therapy. A
minimum 2-log reduction (range, 2.1 to 3.87 log) of virus in
plasma was maintained through 12 weeks in 12 (75%) of the 16
infants (5 infants aged #3 months and 7 children aged .3
months to 2 years). In the remaining four infants, initial re-
ductions in plasma HIV-1 RNA copy numbers were not main-
tained. Potential explanations for the observed rebounds in
plasma HIV-1 load in these four children include incomplete
adherence to the prescribed medication regimens and the se-
lection of drug-resistant variants. Since these factors could
affect the calculated viral clearance rates, these children were
excluded from analysis. The calculation of HIV-1 kinetic pa-
rameters for the 12 children (Table 1) who had sustained
reductions in plasma HIV-1 RNA copy numbers form the basis
of this report.
All 12 infants were of Centers for Disease Control and
Prevention clinical category N, A, or B, and the percentage of
peripheral blood CD4 T cells ranged from 14 to 48 at the time
of entry into the study. Four study participants (all ,3 months
of age) had received prior antiretroviral therapy, consisting of
ZDV alone, ranging in duration from 15 days to 10 weeks. One
infant received ZDV until the time of study enrollment; for the
three remaining infants who had received prior ZDV therapy,
ZDV was discontinued 3 days, 9 days, and 5 weeks, respec-
tively, prior to the time of study enrollment.
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Antiretroviral activity of ZDV-3TC-NVP. Baseline plasma
HIV-1 RNA copy numbers were defined as the arithmetic
mean of the plasma HIV-1 RNA measured just prior to the
initiation of study therapy and at least one other measurement
obtained within the prior 2 weeks. Baseline plasma HIV-1
RNA copy numbers ranged from 104.70 to 106.82 (median, 105.8
per ml) (Table 1). These plasma HIV-1 RNA copy numbers
are of similar magnitude to those reported by others for the
age range studied (15, 16, 25). Pretreatment plasma HIV-1
RNA levels were similar for the two age cohorts (for #3
months, range of 104.81 to 106.82 and median of 105.9; for .3
months, range of 104.70 to 106.47 and median of 105.70), even
though four of the five infants of #3 months of age had re-
ceived ZDV therapy prior to study enrollment.
Blood samples for the measurement of plasma HIV-1 RNA
levels were drawn just prior to therapy and at 3 and 8 h; at 1,
3, 7, 14, and 28 days; and then every 28 days after the initiation
of therapy. Little change (,0.5 log) in plasma HIV-1 RNA
level was observed over the first 24 h of therapy. Thereafter, a
biphasic reduction in plasma HIV-1 RNA copy numbers was
observed (Fig. 1). The initial decline in plasma HIV-1 RNA
copy number was exponential, rapid, and profound and was
followed by a slower, exponential second-phase decline. Over
the first week of therapy, plasma HIV-1 RNA copy numbers
fell 0.61 (76% reduction) to 2.45 (99.6% reduction) logs, with
a median decrease of 1.85 logs (98.69% reduction). By the end
of the second week of therapy, plasma HIV-1 RNA copy num-
bers had fallen 1.22 (94% reduction) to 2.62 (99.76% reduc-
tion) logs, with a median reduction of 2.12 logs (99.3% reduc-
tion). After 12 weeks of therapy, plasma HIV-1 RNA copy
numbers had fallen 2.21 (99.4% reduction) to 3.87 (99.99%
reduction) logs, with a median reduction of 2.93 logs (99.85%
reduction). The magnitude and rapidity of the observed reduc-
tions in plasma HIV-1 copy numbers after the initiation of
therapy attest to the antiviral potency of the regimen.
Kinetics of plasma HIV-1 decay following the initiation of
ZDV-3TC-NVP therapy. The biphasic decay observed in this
study is similar to that described by Perelson and colleagues
following the initiation of potent combination antiretroviral
therapies in adults (18). We therefore used a model similar to
that of Perelson et al. to calculate plasma viral load decay rates
during each phase of viral load reduction. As in previous stud-
ies (18, 19), if the treatment is assumed to completely block
new viral replication, the first phase decay rate (d) represents
the death rate of productively infected cells and the second
phase decay rate (m) represents the death rate of long-lived or
latently infected cells. In our calculations, we considered the
long-lived and latently infected cells as one cellular compart-
ment since they cannot be distinguished by using plasma
HIV-1 RNA measurements alone.
The following equation was used to calculate the first (d) and
second (m) phase decay constants:
V~t! 5 V0 @Ae2dt 1 Be2mt 1 ~1 2 A 2 B!e2ct# (1)
FIG. 1. Plasma HIV-1 RNA copy numbers (log 10 scale) for four patients. The circles represent the observed data, and the solid lines are the fitted curves. Under
the perfect treatment assumption, d1 5 d, d2 5 m, and t1/2 represents the corresponding half-lives.
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where V(t) is the measured number of RNA copies in the
plasma at time t, V0 is the measured number of RNA copies in
the plasma prior to the initiation of therapy, and e52.718. The
nonlinear least squares method was used to fit the above model
to each individual’s viral load data.
Because of limitations in the amount of blood that could be
drawn, particularly from young infants, we were unable to
obtain adequate numbers of specimens to estimate the clear-
ance rate (c) of free virions. Simulation studies (3a) using a c
of 3 to 100 suggest little variability in the estimate of d and m
when c is .5. We used a c of 3 per day to allow comparison of
our data with those from adult studies by Perelson and col-
leagues (18).
Since a majority of the infants and children were studied
close to the time of the acquisition of infection, their viral load
and CD4 T-cell numbers were not likely to be in a steady state
prior to the initiation of therapy. We therefore used a model
not restricted by the steady-state condition in which the terms
A and B in equation 1 are treated as arbitrary constants. Fur-
ther discussion regarding the evaluation of the non-steady-
state condition can be found in the work of Wu and Ding (29).
Both phases of viral load reduction appeared to be more
rapid in the older group of infants (.3 months to 2 years) than
in the younger group of infants (#3 months). Overall, first-
phase viral decay rates ranged from 0.26 to 2.02 (median, 1.03),
which corresponds to calculated half-lives ranging from 0.34 to
2.69 (median, 0.66) days. First-phase viral decay rates were
notably lower in the younger group of infants (range, 0.26 to
1.03; median, 0.56) than in the older group of infants (range,
0.97 to 2.02; median, 1.14). These values correspond to calcu-
lated half-lives (i.e., the time necessary for reduction of the
plasma virus level by one-half) ranging from 0.67 to 2.69 days
(median, 1.23 days) in the younger group and 0.34 to 0.71 days
(median, 0.61 days) in the older group. The difference in first-
phase viral decay rates between the younger and older children
was examined by using the Wilcoxon rank sum test and was
found to be highly significant (P 5 0.0051) (Table 1). No ap-
parent correlations were observed between the first-phase de-
cay rate (d) and any of the following: baseline plasma RNA
levels, peripheral blood CD4 T-cell counts (absolute numbers
or percentages), the percentage of peripheral blood CD4 T
cells coexpressing CD45RA (naive CD4 T cells) or CD45RO
(memory CD4 T cells), peripheral blood CD8 T-cell counts
(absolute numbers or percentages), or the percentage of pe-
ripheral blood CD8 T cells coexpressing the activation antigen
DR (data not shown).
The transition time between first- and second-phase decay
ranged from 3 to 17 days, with a median of 5 days. Second-
phase viral decay rates ranged from 0.02 to 0.15 (median, 0.06),
which correspond to calculated half-lives ranging from 4.68 to
33.26 days (median, 9.3 days). Again, the second-phase decay
rates were notably lower in the younger group (range, 0.02 to
0.04; median, 0.04) than in the older group (range, 0.06 to 0.15;
median, 0.06). These values correspond to calculated half-lives
ranging from 15.38 to 33.26 days (median, 17.17 days) in the
younger group and 4.68 to 12.26 days (median, 11.27 days) in
the older group. The difference in second-phase viral decay
rates between the younger and older children was also exam-
ined by using the Wilcoxon rank sum test and was found to be
highly significant (P 5 0.0025). In addition, a highly significant
positive linear correlation was found between age at initiation
of therapy and the second-phase decay rate (P 5 0.0052) (Fig.
2). No apparent correlations were observed between the sec-
ond-phase decay constant (m) and any of the following: base-
line plasma RNA levels, peripheral blood CD4 T-cell counts
(absolute numbers or percentages), the percentage of periph-
eral blood CD4 T cells coexpressing CD45RA (naive CD4 T
cells) or CD45RO (memory CD4 T cells), peripheral blood
CD8 T-cell counts (absolute numbers or percentages), or the
percentage of peripheral blood CD8 T cells coexpressing the
activation antigen DR (data not shown).
DISCUSSION
In this study, potent antiretroviral therapies were used to
probe the kinetics of HIV-1 replication in infants and children
aged 15 days to 2 years with limited prior antiretroviral ther-
apy. Frequent blood sampling to measure plasma HIV-1 RNA
copy number following the initiation of potent antiretroviral
therapy allowed the calculation of the first detailed evaluation
of viral kinetics in young, HIV-1-infected infants and children.
The clearance of HIV-1 virions in plasma following the
initiation of therapy was biphasic. The majority (.90%) of
virus in plasma was cleared during an initial rapid, exponential
decline. A slower, exponential second-phase decline was then
observed. This pattern of virion clearance is similar to that
previously described following the initiation of potent combi-
nation antiretroviral therapy in cohorts of adults experiencing
primary infection (9) and in adults with established disease
(18). The consistency in this pattern is striking given the diver-
sity in age, viral load, disease stage, and CD4 counts of the
patient populations studied, in addition to the various regi-
mens used.
As suggested by Ho, Perelson, and coworkers (6, 18, 19), the
observed biphasic pattern of viral clearance likely represents
two distinct cellular sources for plasma virions: short-lived,
productively infected cells (CD4 T cells; first phase) and long-
lived cells with stably integrated HIV-1 provirus (tissue mac-
rophages, dendritic cells, or latently infected CD4 T cells un-
dergoing activation; second phase). Alternatively, the biphasic
decay following the initiation of therapy could represent an
exponential decay of viral production by a single cellular
source with a decreasing exponent over time due to a reduction
in either the number of virus-producing cells or the ability of
the cells to produce virus (e.g., an increased number of cells
moving from the activated state to a resting state).
Viral decay rates were used to calculate half-lives for viral
turnover. During the first phase of viral decay (representing
.90% of plasma virus), half of the plasma virus turned over
approximately every 30 h on average in the younger group and
approximately every 14 h on average in the older group. These
estimates are likely a composite of the clearance of free virions
and short-lived, productively infected cells. Due to limitations
FIG. 2. Correlation between the second-phase viral decay rate (m) and the
age of patients at the time of study entry.
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in the blood volumes that we were able to obtain from these
young children, we were unable to obtain samples at a suffi-
cient frequency to distinguish the separate contributions of the
free virions and the short-lived productively infected cells.
Data from adult studies suggest that d primarily reflects the
clearance rate of short-lived productively infected cells; the
calculated first-phase half-lives measured in the young infants
are comparable to the half-lives of productively infected CD4
T cells reported in similar studies of adults. Overall, these data
suggest rates of HIV-1 production and turnover that are at
least as rapid as those previously reported for adults. Interest-
ingly, the half-lives in the older infants and children are ap-
proximately half those reported in adults, suggesting even
more rapid production and turnover of HIV-1 in plasma in
these children.
Several hypotheses could be raised to explain the observed
age-related differences in clearance rates. The slower clear-
ance of HIV-1 from the younger infants might reflect a re-
duced activity of the regimen in those infants. Plasma NVP
levels were measured at several time points during the study;
plasma NVP levels in the younger infants were similar to or
exceeded those measured in the older infants (data not shown).
Differences in NVP absorption and metabolism are thus un-
likely explanations for the observed age-related differences in
clearance rates.
Alternatively, the slower clearance rates observed in the
younger infants could reflect a lesser activity of the regimen
due to the effects of prior therapy (e.g., preexisting resistance
mutations). In this regard, it must be noted that while none of
the older children had received antiretroviral therapy prior to
study entry, the majority of the young infants had received
ZDV therapy prior to their enrollment in the study. Sequenc-
ing of the reverse transcriptase gene from viral isolates ob-
tained prior to the initiation of therapy is under way. This
should allow the assessment of whether mutations associated
with resistance to any of the reverse transcriptase inhibitors
used in this study might have influenced the response to ther-
apy.
A difference in the proportion of virus produced by different
cellular sources and a differential susceptibility of these sources
to the effects of antiretroviral therapies could also explain the
observed age-related differences in viral kinetics. Likewise,
age-related differences in the number of cells capable of
supporting productive infection (particularly activated CD4 T
cells) might explain the observed age-related differences. Fi-
nally, less vigorous or delayed development of HIV-1-specific
immune responses (most notably antibody-dependent cellular
cytotoxicity and cytotoxic T-lymphocyte responses [11, 21, 22])
have been described in young infants and could contribute to
the less rapid clearance of HIV-1 following the initiation of
antiretroviral therapy. The analysis of additional cohorts of
infants who have begun therapy with quadruple-therapy regi-
mens (ZDV-3TC-NVP-abacavir or stavudine-3TC-NVP-nelfi-
navir) is currently under way and should allow us to distinguish
between these possibilities.
Based on their initial studies with adults, Perelson et al. (19)
suggested that the use of potent combination therapies that
arrest HIV-1 replication might allow the eradication of HIV-1
infection over time; a minimum of 2 to 3 years of continuous
therapy was estimated to be necessary to clear HIV-1 from the
two major cellular compartments (productively infected T cells
and the long-lived cell population). In the present study, ex-
trapolation of the first- and second-order viral decay rates in
infants suggest a time to viral extinction of 10 to 74 days
(median, 20 days) in the first compartment (productively in-
fected T cells) and from 102 to 721 days (median, 303 days) in
the second compartment (long-lived infected cells). As we (10)
and others (5, 6, 28) have noted, however, none of the regi-
mens studied to date are capable of eradicating an integrated
HIV-1 genome from infected cells. These cells, then, represent
a small but potentially significant barrier to the eradication of
infection from an individual. Sufficient blood samples to esti-
mate the size of this potentially long-lived pool of infected cells
in infants and children were not obtained in this study but are
currently being collected for cohorts of infants who have begun
therapy with quadruple-therapy regimens (ZDV-3TC-NVP-
abacavir or stavudine-3TC-NVP-nelfinavir).
In summary, HIV-1 turnover and kinetics in plasma were
studied in children aged 15 days to 2 years. Calculated rates of
HIV-1 turnover were at least as rapid as those previously
described in adults; turnover rates were more rapid in older
infants and children than in younger infants. These data con-
firm the central role of HIV-1 replication in the pathogenesis
of vertical HIV-1 infection and reinforce the importance of
early, potent combination therapies for the long-term control
of HIV-1 replication.
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